Polythiazide (3 brand names, 2 dosage forms, 1 route)
Available dosage forms: TABLET, CAPSULE.
Routes of administration: ORAL.
Brand Names
- MINIZIDE
- RENESE
- RENESE-R
Boxed Warning
This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.
Indications and Usage
Hypertension (see box warning).
Dosage and Administration
As determined by individual titration (see box warning).Initial dosages of the combination should conform to those dosages of the individual components established during titration.Maintenance dosages range from ½ tablet to 2 tablets daily. Dosage of other antihypertensive agents, particularly ganglionic blockers, that are used concomitantly should be reduced.
Contraindications
A. Related to polythiazideAdvanced renal or hepatic failure. Hypersensitivity to this or other sulfonamide derivatives.B. Related to reserpineDemonstrated hypersensitivity.Patients with a history of mental depression.Demonstrated peptic ulcer or ulcerative colitis.
Adverse Reactions
The following adverse reactions have been observed, but there is not enough systemic collection of data to support an estimate of their frequency.
Overdosage
One case of RENESE-R overdosage is reported after ingestion of an unknown number of tablets. Electrolyte replacement therapy was successful in treating the symptoms.